ReadeRx Therapeutics

Company Overview

Snapshot

Founded in January 2023, ReadeRx Therapeutics operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on the development of RNA-based cancer therapeutics. As of July 2026, ReadeRx Therapeutics ceased to operate.

Business overview

ReadeRx Therapeutics is developing small molecule inhibitors that target the RNA binding protein IGF2BP1 as a novel treatment for cancer. The company's core technology focuses on inhibiting IGF2BP1, an oncofetal RNA binding protein that is reactivated in many cancers, promoting pro-oncogenic processes. By stabilizing key pro-oncogenic RNAs, IGF2BP1 plays a pivotal role in tumor development. ReadeRx Therapeutics aims to serve the pharmaceuticals and life sciences markets within the Health Tech & Life Sciences sector, specifically in oncology and cancer therapy.

Company Intelligence Q&A

What is ReadeRx Therapeutics' primary focus?

ReadeRx Therapeutics is focused on developing RNA-based cancer therapeutics, specifically small molecule inhibitors targeting the RNA binding protein IGF2BP1.

When was ReadeRx Therapeutics founded?

ReadeRx Therapeutics was founded in January 2023.

What is the current operational status of ReadeRx Therapeutics?

ReadeRx Therapeutics ceased to operate in July 2026.

What is the company's employee size?

ReadeRx Therapeutics operates with 1–10 employees.

What is the strategic approach of ReadeRx Therapeutics in cancer treatment?

ReadeRx Therapeutics' strategic approach involves inhibiting IGF2BP1, an oncofetal RNA binding protein that is reactivated in many cancers and plays a critical role in stabilizing pro-oncogenic RNAs to promote tumor growth.